Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06038409 · ClinicalTrials.gov registry record

Ketamine Treatment Plans for Chronic Conditions

A clinical trial of Chronic Pain and Anxiety Disorders, sponsored by RIVER Foundation.

Recruiting
Registry status
500
Enrollment target
1
Study location

NCT06038409: Recruiting study of Chronic Pain and Anxiety Disorders, sponsored by RIVER Foundation.

NCT06038409 is a study of Chronic Pain and Anxiety Disorders that is actively recruiting participants, run by RIVER Foundation. The registered enrollment target is 500 participants, below the 771-participant average among 301 other Chronic Pain trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06038409, a study of Chronic Pain and Anxiety Disorders, is actively recruiting participants, sponsored by RIVER Foundation.

RECRUITING
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

A study aimed to assess the efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the study plan of those with chronic conditions who are receiving ketamine.

Primary Outcome

Compare and Contrast the different methods and uses of ketamine for acceptability for the route of use. (ie oral sublingual or nasal spray)

Interventions

  • DRUG Ketamine

Study Locations (1)

Montana

  • RIVER Telehealth - Helena

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2023-01-01
Est. Completion 2029-06-01
RIVER Foundation

2 total trials

What NCT06038409 shows while recruiting

NCT06038409 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 771-participant average among 301 other Chronic Pain trials with a reported enrollment target (35% lower).

The record links to 4 conditions, with Chronic Pain appearing as the primary indexed condition, and to 1 intervention - of which Ketamine is the first listed.

NCT06038409 reports a single indexed study location in Montana.

Frequently Asked Questions

What is clinical trial NCT06038409 about?

NCT06038409 is a clinical study titled "Ketamine Treatment Plans for Chronic Conditions". A study aimed to assess the efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the study plan of those with chronic conditions who are receiving ketamine.

What is the current status of trial NCT06038409?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-01-01. Estimated completion is 2029-06-01.

What conditions does trial NCT06038409 study?

This clinical trial studies the following conditions: Chronic Pain, Anxiety Disorders, Chronic Disease, Depressive Disorder.

What interventions are being tested in trial NCT06038409?

The interventions under investigation include: Ketamine (DRUG).

Who is sponsoring clinical trial NCT06038409?

This trial is sponsored by RIVER Foundation, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06038409 being conducted?

This trial has 1 study location across Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06038409's enrollment target sits among peer trials

500 18th of 301 higher than 280 of 301 other Chronic Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06038409, the US trial registry maintained by the National Library of Medicine. NCT06038409 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.